Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Plus de 40 000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
0,002 (c) EUR
Ouverture théorique 0,000

FR0011799907 GV

Euronext Paris données temps réel
  • ouverture


  • clôture veille


  • + haut


  • + bas


  • volume


  • capital échangé


  • valorisation

    1 MEUR

  • dernier échange

    03.11.23 / 17:35:10

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?



  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?



  • rendement estimé 2024


  • PER estimé 2024

    Qu'est-ce que le PER ?



  • dernier dividende

    A quoi correspond le montant du dernier dividende versé ?



  • date dernier dividende


  • Éligibilité

    Qu'est-ce que le PEA ?


    Qu'est-ce que le PEA-PME ?


    Non éligible Boursobank

  • + Alerte

  • + Portefeuille

  • + Liste

Retour au sujet GENOMIC VISION

GENOMIC VISION : Le test HPV va bientôt....

30 déc. 2018 20:15

prendre une place importante dans la prévention!!!!!

HPV type 16 or 18 in young women predicts risk of cervical cancer
Published 2018-12-10 06:01. Updated 2018-12-10 11:07Denna sida på svenska
Maria Fröberg, Sona Andersson, Karen Belkic och Ellinor Östensson. Foto: Ulf Sirborn
Maria Fröberg, Sona Andersson, Karen Belkic and Ellinor Östensson. Photo: Ulf Sirborn

The human papilloma virus (HPV) can cause cervical cancer. According to new guidelines in Sweden, women over thirty therefore undergo initial screening for the virus rather than a smear test. But younger women also have a much higher risk of pre-cancerous lesions if they carry HPV 16 or 18, a study from Karolinska Institutet in Sweden published in the scientific journal Cancer shows.

Four out of five women of fertile age are infected at some time in their lives with HPV. Most of these infections clear on their own, but for some five per cent of the women, the infection turns chronic. Chronic HPV infection can cause pre-cancerous lesions and cancer of the cervix. HPV types 16 and 18 cause some 70 per cent of all cases of cervical cancer and the majority of high-grade pre-cancerous lesions. There are also several other high-risk HPV types that can cause pre-cancerous lesions and cervical cancer.

So that doctors can catch pre-cancerous lesions in time, women in Sweden between the ages of 23 and 64 are screened using ectocervical smear tests. If the smear test is abnormal, the sample is tested for HPV. According to new guidelines, screening from the age of 32 is to take the form, in the first instance, of an HPV test instead. If the woman tests HPV positive, a cell sample is then taken that, if aberrant, occasions further gynaecological investigation. However, in the event of a normal cell test but a positive HPV test, the woman is invited only routinely to screening after three to seven years, depending on age.
Normal smear tests are no guarantee

Sonia Andersson. Photo: Ulf Sirborn
"This is odd when we know that HPV is associated with cervical cancer," says Sonia Andersson, professor of gynaecology at the Department of Women's and Children's Health, Karolinska Institutet. "So we wanted to examine the cervical cancer risk for patients with normal smear results."

The study included over 9,000 normal smear tests from women between the ages of 20 and 60 who took their tests under the Swedish screening programme from 2005 to 2007. During the follow-up period ending 2014, almost 100 of these women developed high-grade pre-cancerous lesions or in a few cases actual cervical cancer. These patients' cell samples were then tested for HPV and compared individually with samples from healthy women. The researchers found that women over the age of 30 who were carriers of high-risk HPV had, regardless of HPV type, an eight times higher risk of developing high-grade pre-cancerous lesions or cancer than women with negative HPV findings.

"Normal cell tests are therefore no guarantee that a woman won't develop precancerous changes that can lead to cervical cancer," says Professor Andersson. "So we need to follow up women with positive HPV findings more frequently."
Should test for HPV type

Women below the age of 30 who tested positive for HPV types 16 and 18 had a much higher risk of developing high-grade pre-cancerous lesions or cervical cancer compared to women with negative HPV findings. The HPV tests used in screening programmes today do not show which type of HPV a woman is carrying, only that she has a high-risk type of the virus.

"This should be changed. If we test for HPV type, we can screen low-risk individuals less often and instead follow up younger carriers of HPV 16 or 18 and older HPV-positive women more often. In the USA, they're called in for a new HPV test within the year."

"It should be remembered that most HPV infections clear on their own, including HPV 16/18," explains Professor Andersson. "But HPV is the most common risk factor for developing cervical cancer and should be followed up methodically. In this way, more pre-cancerous lesions can be treated on time and more cases of cancer prevented."

The study was conducted in association with the University of Ljubljana, Slovenia, and the Scientific Institute of Public Health in Brussels, Belgium and financed with grants from the Swedish Cancer Society, Karolinska Institutet, Stockholm County Council and the King Gustaf V Jubilee Foundation.

"The impact of HPV status on development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at baseline: 9-year Swedish nested case control follow-up study"
Maria Fröberg, Ellinor Östensson, Karen Belki?, Anja Oštrbenk, Mario Poljak, Miriam Mints, Marc Arbyn, Sonia Andersson.
Cancer, online 10 December 2018, doi: 10.1002/cncr.31788.

0 réponse

Signaler le message


Qui a recommandé ce message ?

Retour au sujet GENOMIC VISION

Mes listes

Cette liste ne contient aucune valeur.